Investor Overview


Corporate Profile

Tocagen is a clinical-stage, cancer-selective gene therapy company developing first-in-class, broadly applicable product candidates designed to activate a patient’s immune system against their own cancer from within. Tocagen is currently studying its lead product candidate, Toca 511 & Toca FC, in a Phase 2/3 clinical trial for the treatment of patients with recurrent high grade glioma (HGG), a type of brain cancer with limited treatment options. Toca 511 & Toca FC has been granted Breakthrough Therapy Designation for the treatment of patients with recurrent HGG by the FDA.
NASDAQ GS TOCA (Common Stock)
$12.540.00
Stock chart for: TOCA.O.  Currently trading at $12.54 with a 52 week high of $17.95 and a 52 week low of $10.25.
06/27/17 4:00 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.

Recent News

View All  

Complementary Preclinical Studies Published in Neuro-Oncology Demonstrate Immune Activation Mechanism of Tocagen's Toca 511 & Toca FC

06/19/17

Read More

Tocagen Reports First Quarter 2017 Financial and Business Results

05/23/17

Read More

Tocagen Presents Data at the American Society of Gene and Cell Therapy 20th Annual Meeting

05/11/17

Read More

Recent Presentation

View All  
DateTitle
06/22/17
Corporate Presentation – June 20, 2017
Download Documentation
PDF

Upcoming Events

View All  
There are currently no events scheduled.